{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:17:30Z","timestamp":1780647450961,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Asociaci\u00f3n La Cuadri del Hospi","award":["BC\/A\/17\/008"],"award-info":[{"award-number":["BC\/A\/17\/008"]}]},{"name":"EITB Media AND BIOEF, SAU","award":["BIO20\/CI\/015\/BCB and BIO20\/CI\/011\/BCB"],"award-info":[{"award-number":["BIO20\/CI\/015\/BCB and BIO20\/CI\/011\/BCB"]}]},{"name":"Jes\u00fas de Gangoiti Barrera Foundation","award":["FJGB18\/004 and FJGB19\/001"],"award-info":[{"award-number":["FJGB18\/004 and FJGB19\/001"]}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"crossref","award":["54\/2018"],"award-info":[{"award-number":["54\/2018"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n La Caixa with Ni\u00f1os Contra el C\u00e1ncer"},{"DOI":"10.13039\/501100008545","name":"Asociaci\u00f3n Pablo Ugarte","doi-asserted-by":"publisher","award":["APU-osteosarcoma"],"award-info":[{"award-number":["APU-osteosarcoma"]}],"id":[{"id":"10.13039\/501100008545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"crossref","award":["2021111030"],"award-info":[{"award-number":["2021111030"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genetic predisposition is an important risk factor for cancer in children and adolescents but detailed associations of individual genetic mutations to childhood cancer are still under intense investigation. Among pediatric cancers, sarcomas can arise in the setting of cancer predisposition syndromes. The association of sarcomas with these syndromes is often missed, due to the rarity and heterogeneity of sarcomas and the limited search of cancer genetic syndromes. This study included 43 pediatric and young adult patients with different sarcoma subtypes. Tumor profiling was undertaken using the Oncomine Childhood Cancer Research Assay (Thermo Fisher Scientific). Sequencing results were reviewed for potential germline alterations in clinically relevant genes associated with cancer predisposition syndromes. Jongmans\u00b4 criteria were taken into consideration for the patient selection. Fifteen patients were selected as having potential pathogenic germline variants due to tumor sequencing that identified variants in the following genes: <jats:italic>CDKN2A<\/jats:italic>, <jats:italic>NF1, NF2, RB1<\/jats:italic>, <jats:italic>SMARCA4<\/jats:italic>, <jats:italic>SMARCB1<\/jats:italic> and <jats:italic>TP53<\/jats:italic>. The variants found in <jats:italic>NF1<\/jats:italic> and <jats:italic>CDKN2A<\/jats:italic> in two different patients were detected in the germline, confirming the diagnosis of a cancer predisposition syndrome. We have shown that the results of somatic testing can be used to identify those at risk of an underlying cancer predisposition syndrome.<\/jats:p>","DOI":"10.1038\/s41598-023-29982-2","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:04:35Z","timestamp":1676894675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of germline cancer predisposition variants in pediatric sarcoma patients from somatic tumor testing"],"prefix":"10.1038","volume":"13","author":[{"given":"Piedad","family":"Alba-Pav\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lide","family":"Ala\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gutierrez-Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Garc\u00eda-Obreg\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Im\u00edzcoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gonz\u00e1lez-Urdiales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizpea","family":"Echebarria-Barona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Lopez Almaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zaldumbide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Astigarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pati\u00f1o-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatz","family":"Villate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"29982_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ajmg.a.38142","volume":"173","author":"T Ripperger","year":"2017","unstructured":"Ripperger, T. et al. Childhood cancer predisposition syndromes\u2014A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am. J. Med. Genet. 173, 1017\u20131037 (2017).","journal-title":"Am. J. Med. Genet."},{"key":"29982_CR2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336\u20132346 (2015).","journal-title":"N. Engl. J. Med."},{"key":"29982_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s43018-021-00172-1","volume":"2","author":"EM Fiala","year":"2021","unstructured":"Fiala, E. M. et al. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nat. Cancer 2, 357\u2013365 (2021).","journal-title":"Nat. Cancer"},{"key":"29982_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-genom-083118-015415","volume":"20","author":"SE Plon","year":"2019","unstructured":"Plon, S. E. & Lupo, P. J. Genetic predisposition to childhood cancer in the genomic era. Annu. Rev. Genom. Hum. Genet. 20, 241\u2013263 (2019).","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"29982_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14737159.2017.1316665","volume":"17","author":"L-M Johnson","year":"2017","unstructured":"Johnson, L.-M. et al. Ethical considerations surrounding germline next-generation sequencing of children with cancer. Expert Rev. Mol. Diagn. 17, 523\u2013534 (2017).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"29982_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","volume":"28","author":"U Tabori","year":"2010","unstructured":"Tabori, U. et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. JCO 28, 1995\u20132001 (2010).","journal-title":"JCO"},{"key":"29982_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"The European Reference Network GENTURIS","year":"2020","unstructured":"The European Reference Network GENTURIS et al. Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes. Eur. J. Hum. Genet. 28, 1379\u20131386 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"29982_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/1078-0432.CCR-10-1795","volume":"17","author":"F Bourdeaut","year":"2011","unstructured":"Bourdeaut, F. et al. Frequent hSNF5\/INI1 germline mutations in patients with Rhabdoid tumor. Clin. Cancer Res. 17, 31\u201338 (2011).","journal-title":"Clin. Cancer Res."},{"key":"29982_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10689-021-00229-1","volume":"20","author":"MC Fr\u00fchwald","year":"2021","unstructured":"Fr\u00fchwald, M. C. et al. Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: A report from the SIOPE Host Genome Working Group. Fam. Cancer 20, 305\u2013316 (2021).","journal-title":"Fam. Cancer"},{"key":"29982_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1634\/theoncologist.2016-0079","volume":"21","author":"M Farid","year":"2016","unstructured":"Farid, M. & Ngeow, J. Sarcomas Associated with genetic cancer predisposition syndromes: A review. Oncologist 21, 1002\u20131013 (2016).","journal-title":"Oncologist"},{"key":"29982_CR11","unstructured":"Soft tissue and bone tumours. (OMS, 2020)."},{"key":"29982_CR12","first-page":"1","volume":"2012","author":"GT Calvert","year":"2012","unstructured":"Calvert, G. T. et al. At-risk populations for osteosarcoma: The syndromes and beyond. Sarcoma 2012, 1\u20139 (2012).","journal-title":"Sarcoma"},{"key":"29982_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","volume":"6","author":"L Mirabello","year":"2020","unstructured":"Mirabello, L. et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 6, 724 (2020).","journal-title":"JAMA Oncol."},{"key":"29982_CR14","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1038\/s41467-018-05537-2","volume":"9","author":"MJ Machiela","year":"2018","unstructured":"Machiela, M. J. et al. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nat. Commun. 9, 3184 (2018).","journal-title":"Nat. Commun."},{"key":"29982_CR15","doi-asserted-by":"publisher","first-page":"e0237792","DOI":"10.1371\/journal.pone.0237792","volume":"15","author":"S-H Lin","year":"2020","unstructured":"Lin, S.-H. et al. Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE 15, e0237792 (2020).","journal-title":"PLoS ONE"},{"key":"29982_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ng.1085","volume":"44","author":"S Postel-Vinay","year":"2012","unstructured":"Postel-Vinay, S. et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat. Genet. 44, 323\u2013327 (2012).","journal-title":"Nat. Genet."},{"key":"29982_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ajhg.2022.04.007","volume":"109","author":"R Gillani","year":"2022","unstructured":"Gillani, R. et al. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am. J. Hum. Genet. 109, 1026\u20131037 (2022).","journal-title":"Am. J. Hum. Genet."},{"key":"29982_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/gim.2016.206","volume":"19","author":"AS Brohl","year":"2017","unstructured":"Brohl, A. S. et al. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet. Med. 19, 955\u2013958 (2017).","journal-title":"Genet. Med."},{"key":"29982_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/pbc.25726","volume":"62","author":"R Zimmerman","year":"2015","unstructured":"Zimmerman, R., Schimmenti, L. & Spector, L. A catalog of genetic syndromes in childhood cancer. Pediatr. Blood Cancer 62, 2071\u20132075 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"29982_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jnci\/djaa204","volume":"113","author":"H Li","year":"2021","unstructured":"Li, H. et al. Germline cancer predisposition variants in pediatric rhabdomyosarcoma: A report from the Children\u2019s oncology group. J. Natl. Cancer Inst. 113, 875\u2013883 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"29982_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/his.12280","volume":"64","author":"CM Coffin","year":"2014","unstructured":"Coffin, C. M., Davis, J. L. & Borinstein, S. C. Syndrome-associated soft tissue tumours. Histopathology 64, 68\u201387 (2014).","journal-title":"Histopathology"},{"key":"29982_CR22","doi-asserted-by":"publisher","first-page":"pkaa018","DOI":"10.1093\/jncics\/pkaa018","volume":"4","author":"S Klek","year":"2020","unstructured":"Klek, S. et al. Genetic Counseling and germline testing in the era of tumor sequencing: A cohort study. JNCI Cancer Spectr. 4, pkaa018 (2020).","journal-title":"JNCI Cancer Spectr."},{"key":"29982_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41525-020-00160-x","volume":"5","author":"M Guti\u00e9rrez-Jimeno","year":"2020","unstructured":"Guti\u00e9rrez-Jimeno, M. et al. Somatic and germline analysis of a familial Rothmund\u2013Thomson syndrome in two siblings with osteosarcoma. NPJ Genom. Med. 5, 51 (2020).","journal-title":"NPJ Genom. Med."},{"key":"29982_CR24","doi-asserted-by":"publisher","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","volume":"111","author":"JA Perry","year":"2014","unstructured":"Perry, J. A. et al. Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma. Proc. Natl. Acad. Sci. USA 111, E5564\u2013E5573 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"29982_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ccell.2022.08.022","volume":"40","author":"AH Nassar","year":"2022","unstructured":"Nassar, A. H. et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell 40, 1161-1172.e5 (2022).","journal-title":"Cancer Cell"},{"key":"29982_CR26","doi-asserted-by":"publisher","first-page":"8940","DOI":"10.1038\/ncomms9940","volume":"6","author":"M Kovac","year":"2015","unstructured":"Kovac, M. et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat. Commun. 6, 8940 (2015).","journal-title":"Nat. Commun."},{"key":"29982_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/gcc.20817","volume":"49","author":"AB Mohseny","year":"2010","unstructured":"Mohseny, A. B. et al. Small deletions but not methylation underlie CDKN2A\/p16 loss of expression in conventional osteosarcoma. Genes Chromosom. Cancer 49, 1095\u20131103 (2010).","journal-title":"Genes Chromosom. Cancer"},{"key":"29982_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9440(10)65556-3","volume":"153","author":"GP Nielsen","year":"1998","unstructured":"Nielsen, G. P., Burns, K. L., Rosenberg, A. E. & Louis, D. N. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am. J. Pathol. 153, 159\u2013163 (1998).","journal-title":"Am. J. Pathol."},{"key":"29982_CR29","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: The Catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"29982_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cup.13689","volume":"47","author":"A Toussi","year":"2020","unstructured":"Toussi, A., Mans, N., Welborn, J. & Kiuru, M. Germline mutations predisposing to melanoma. J. Cutan. Pathol. 47, 606\u2013616 (2020).","journal-title":"J. Cutan. Pathol."},{"key":"29982_CR31","doi-asserted-by":"publisher","first-page":"djw135","DOI":"10.1093\/jnci\/djw135","volume":"108","author":"H Helgadottir","year":"2016","unstructured":"Helgadottir, H. et al. Germline CDKN2A mutation status and survival in familial melanoma cases. J. Natl. Cancer Inst. 108, djw135 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"29982_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jnci\/95.11.790","volume":"95","author":"M Eskandarpour","year":"2003","unstructured":"Eskandarpour, M. et al. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J. Natl. Cancer Inst. 95, 790\u2013798 (2003).","journal-title":"J. Natl. Cancer Inst."},{"key":"29982_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/jid.2013.270","volume":"134","author":"A Zebary","year":"2014","unstructured":"Zebary, A. et al. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: A GenoMEL study. J. Investig. Dermatol. 134, 287\u2013290 (2014).","journal-title":"J. Investig. Dermatol."},{"key":"29982_CR34","doi-asserted-by":"publisher","first-page":"780264","DOI":"10.3389\/fonc.2021.780264","volume":"11","author":"G Sheng","year":"2021","unstructured":"Sheng, G., Gao, Y., Yang, Y. & Wu, H. Osteosarcoma and metastasis. Front Oncol 11, 780264 (2021).","journal-title":"Front Oncol"},{"key":"29982_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/pcmr.12771","volume":"32","author":"Z Eroglu","year":"2019","unstructured":"Eroglu, Z. et al. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment. Cell Melanoma Res. 32, 458\u2013469 (2019).","journal-title":"Pigment. Cell Melanoma Res."},{"key":"29982_CR36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.14485","volume":"175","author":"MR Sargen","year":"2016","unstructured":"Sargen, M. R., Merrill, S. L., Chu, E. Y. & Nathanson, K. L. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: A case series and review of the literature. Br. J. Dermatol. 175, 785\u2013789 (2016).","journal-title":"Br. J. Dermatol."},{"key":"29982_CR37","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/hed.21911","volume":"35","author":"R Cabanillas","year":"2013","unstructured":"Cabanillas, R. et al. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas. Head Neck 35, E80-84 (2013).","journal-title":"Head Neck"},{"key":"29982_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jmedgenet-2016-104402","volume":"54","author":"F Jouenne","year":"2017","unstructured":"Jouenne, F. et al. Germline CDKN2A\/P16INK4A mutations contribute to genetic determinism of sarcoma. J. Med. Genet. 54, 607\u2013612 (2017).","journal-title":"J. Med. Genet."},{"key":"29982_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13053-021-00178-x","volume":"19","author":"SH Chan","year":"2021","unstructured":"Chan, S. H., Chiang, J. & Ngeow, J. CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition. Hered Cancer Clin. Pract. 19, 21 (2021).","journal-title":"Hered Cancer Clin. Pract."},{"key":"29982_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid, M. et al. Malignant peripheral nerve sheath tumors. Oncologist 19, 193\u2013201 (2014).","journal-title":"Oncologist"},{"key":"29982_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fneur.2020.00368","volume":"11","author":"M Biotteau","year":"2020","unstructured":"Biotteau, M. et al. Sporadic and familial variants in NF1: An explanation of the wide variability in neurocognitive phenotype?. Front. Neurol. 11, 368 (2020).","journal-title":"Front. Neurol."},{"key":"29982_CR42","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz, C. P. et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin. Cancer Res. 23, e38\u2013e45 (2017).","journal-title":"Clin. Cancer Res."},{"key":"29982_CR43","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li, F. P. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48, 5358\u20135362 (1988).","journal-title":"Cancer Res."},{"key":"29982_CR44","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed, R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712\u20134722 (2019).","journal-title":"Clin. Cancer Res."},{"key":"29982_CR45","doi-asserted-by":"publisher","first-page":"e1913900","DOI":"10.1001\/jamanetworkopen.2019.13900","volume":"2","author":"R Karam","year":"2019","unstructured":"Karam, R. et al. Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. JAMA Netw. Open 2, e1913900 (2019).","journal-title":"JAMA Netw. Open"},{"key":"29982_CR46","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1158\/1078-0432.CCR-17-0834","volume":"23","author":"H Druker","year":"2017","unstructured":"Druker, H. et al. genetic counselor recommendations for cancer predisposition evaluation and surveillance in the pediatric oncology patient. Clin. Cancer Res. 23, e91\u2013e97 (2017).","journal-title":"Clin. Cancer Res."},{"key":"29982_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.mayocp.2016.09.008","volume":"92","author":"CJ Klein","year":"2017","unstructured":"Klein, C. J. & Foroud, T. M. neurology individualized medicine: When to use next-generation sequencing panels. Mayo Clin. Proc. 92, 292\u2013305 (2017).","journal-title":"Mayo Clin. Proc."},{"key":"29982_CR48","doi-asserted-by":"publisher","first-page":"997551","DOI":"10.3389\/fneur.2022.997551","volume":"13","author":"KWP Ng","year":"2022","unstructured":"Ng, K. W. P., Chin, H.-L., Chin, A. X. Y. & Goh, D.L.-M. Using gene panels in the diagnosis of neuromuscular disorders: A mini-review. Front. Neurol. 13, 997551 (2022).","journal-title":"Front. Neurol."},{"key":"29982_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"29982_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"29982_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"29982_CR52","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant review with the integrative genomics viewer. Can. Res. 77, e31\u2013e34 (2017).","journal-title":"Can. Res."},{"key":"29982_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"29982_CR54","doi-asserted-by":"publisher","first-page":"e0189881","DOI":"10.1371\/journal.pone.0189881","volume":"12","author":"TM Bennett","year":"2017","unstructured":"Bennett, T. M., M\u2019Hamdi, O., Hejtmancik, J. F. & Shiels, A. Germ-line and somatic EPHA2 coding variants in lens aging and cataract. PLoS ONE 12, e0189881 (2017).","journal-title":"PLoS ONE"},{"key":"29982_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","volume":"22","author":"the SEOM Hereditary Cancer Working Group","year":"2020","unstructured":"the SEOM Hereditary Cancer Working Group et al. SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin. Transl. Oncol. 22, 193\u2013200 (2020).","journal-title":"Clin. Transl. Oncol."},{"key":"29982_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmg.2016.01.008","volume":"59","author":"MCJ Jongmans","year":"2016","unstructured":"Jongmans, M. C. J. et al. Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. Eur. J. Med. Genet. 59, 116\u2013125 (2016).","journal-title":"Eur. J. Med. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29982-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T15:07:54Z","timestamp":1676905674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29982-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["29982"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-29982-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2959"}}